EZH2 and cancer: Therapies targeting oncogenic deregulation of the epigenome, such as EZH2 and BET‐family inhibition, have been successfully used in clinical and preclinical trials for many diverse cancers, such as non‐Hodgkins lymphoma and glioblastoma.27